文献速递乳腺癌放疗放疗物理与技术

低成本聚氨酯薄膜降低高Fitzpatrick分型乳腺癌患者大分割放疗同步瘤床加量所致皮炎严重程度

Effectiveness of Low-Cost Polyurethane Film in Reducing Dermatitis Severity in Breast Cancer Patients With Higher Fitzpatrick Skin Types Undergoing Hypofractionated Irradiation With Simultaneous Integrated Boost: An Intrapatient Randomized Controlled Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-11-02

这项患者内随机对照试验纳入34例接受大分割全乳放疗同步瘤床加量的乳腺癌患者,每例患者半侧乳房覆盖聚氨酯薄膜、另半侧为对照。结果显示薄膜侧CTCAEv5≥2级皮炎发生率在放疗结束时为0%对42.4%(观察者1)和0%对39.4%(观察者2),随访1个月时为12.9%对35.5%和12.9%对32.3%,均P<.05,且患者报告的疼痛等症状显著减轻。

要点

  • 薄膜侧放疗结束时CTCAEv5≥2级皮炎为0%,对照侧为42.4%或39.4%(P<.05)。
  • 随访1个月薄膜侧≥2级皮炎12.9%,对照侧35.5%或32.3%(P<.05)。
  • 薄膜侧患者报告的疼痛、压痛、不适和瘙痒显著减轻(P<.05)。

核心结论

  • 预防性使用聚氨酯薄膜可降低Fitzpatrick 3-5型乳腺癌患者大分割放疗同步瘤床加量所致的急性放射性皮炎严重程度。
  • 该干预还可改善患者报告结局,且未出现3级或4级皮炎。

研究设计与样本

  • 患者内随机对照试验,共纳入34例接受大分割全乳放疗同步瘤床加量的乳腺癌患者。
  • 每例患者半侧乳房覆盖聚氨酯薄膜,另半侧裸露作为对照。
  • 采用CTCAEv5、Catterall皮肤评分和RISRAS评估皮炎严重程度。

主要发现

  • 多数患者Fitzpatrick皮肤分型为4和5型(85.3%),3型占14.7%。
  • 4例患者在第二次放疗分次后出现薄膜外侧缘牵拉性水肿,修剪外侧边缘后3例缓解,1例需完全移除薄膜。
  • 放疗结束时薄膜组CTCAEv5≥2级皮炎为0%,对照侧观察者1为42.4%、观察者2为39.4%(P<.05)。
  • 随访1个月薄膜组≥2级皮炎为12.9%,对照侧观察者1为35.5%、观察者2为32.3%(P<.05)。
  • 放疗结束和随访1个月时,Catterall中位评分2对3、RISRAS中位评分6对7(P<.05);RISRAS患者部分显示薄膜侧疼痛、压痛、不适和瘙痒显著减轻(P<.05)。

关键数值与推荐

  • 放疗结束时CTCAEv5≥2级皮炎发生率:薄膜组0%,对照侧42.4%(观察者1)和39.4%(观察者2),P<.05。
  • 随访1个月≥2级皮炎发生率:薄膜组12.9%,对照侧35.5%(观察者1)和32.3%(观察者2),P<.05。
  • Catterall中位评分薄膜侧2对对照侧3(P<.05),RISRAS中位评分6对7(P<.05)。

临床怎么用

  • 对Fitzpatrick 3-5型接受大分割全乳放疗同步瘤床加量的乳腺癌患者,可考虑预防性使用聚氨酯薄膜以降低急性皮炎严重程度。
  • 使用中需注意薄膜外侧缘可能引起牵拉性水肿,可通过修剪边缘处理,必要时完全移除。

局限性

  • 样本量较小(34例),仅纳入Fitzpatrick 3-5型患者。
  • 采用患者内设计,薄膜侧与对照侧可能受局部皮肤差异影响。
  • 随访时间仅至放疗后1个月,未报告长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation dermatitis is the most common side effect for patients undergoing hypofractionated adjuvant whole breast radiation therapy. We assessed the effectiveness of prophylactic polyurethane film dressings in reducing the radiation dermatitis severity. PATIENTS AND METHODS: In this intrapatient randomized controlled trial, 34 patients were enrolled. Each patient's breast was covered with a polyurethane dressing on one-half, whereas the other bare half served as a control, during hypofractionated whole breast radiation therapy with simultaneous tumor-bed boost. Dermatitis severity was evaluated using the Common Terminology Criteria for Adverse Events version 5 (CTCAEv5), Catterall Skin Scoring Profile, and Radiation-Induced Skin Reaction Assessment Scale (RISRAS). RESULTS: Majority of patients had higher Fitzpatrick skin types, that is, 4 and 5 (85.3%), whereas type 3 comprised 14.7%. Four patients developed stretch edema at the film's lateral border after the second radiation fraction. Trimming the lateral edge resolved the issue in 3 cases, whereas one required complete film removal. At the conclusion of radiation, incidence of CTCAEv5 grade ≥2 dermatitis was 0% in the film group, compared with 42.4% in the control group (P < .05) according to observer 1, and 0% versus 39.4% (P < .05) as per observer 2. At 1-month follow-up, the rates of grade ≥2 dermatitis were 12.9% in the film group versus 35.5% in the control group (P < .05) as assessed by observer 1, and 12.9% versus 32.3% (P < .05) according to observer 2. At the end of radiation and the first-month follow-up, median Catterall Skin Scoring Profile score was 2 versus 3 (P < .05), and median RISRAS score was 6 versus 7 (P < .05). The RISRAS patient component indicated significant reduction in pain, tenderness, discomfort, and itching on the film side at the end of radiation (P < .05). None of the patients developed grade 3 or 4 dermatitis. CONCLUSION: Prophylactic polyurethane film is an affordable intervention in reducing the acute radiation dermatitis severity and improves patient-reported outcomes in breast cancer with Fitzpatrick skin types 3-5.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Harish M, Sethi P, Gunaseelan K, et al. Effectiveness of Low-Cost Polyurethane Film in Reducing Dermatitis Severity in Breast Cancer Patients With Higher Fitzpatrick Skin Types Undergoing Hypofractionated Irradiation With Simultaneous Integrated Boost: An Intrapatient Randomized Controlled Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 41187861. doi:10.1016/j.ijrobp.2025.10.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。